Post on 30-Dec-2015
2015 MBSW 1
Quality Assurance Test of Delivered Dose Uniformity of Multi-dose Spray and
Inhalation Drug Products
Drs. Yi Tsong1, Xiaoyu (Cassie) Dong*1, Meiyu Shen 1& Richard T. Lostritto 2
1: Office of Biostatistics/Office of Translational Sciences, CDER, FDA
2: Office of Pharmaceutical Quality, CDER, FDA
Disclaimer
• This article reflects the views of the authors and should not be construed to represent FDA’s views or policies.
22015 MBSW
3
Outline
I. Introduction
II. USP<601> DDU Test
III. Two One-Sided Tolerance Intervals (TOSTI) DDU Test
IV. FDA Large Sample DDU Proposal
V. Summary
VI. Main References
2015 MBSW
I. Introduction
42015 MBSW
5
Multi-dose Inhaler/Spray• A multi-dose inhaler/spray (MDI) delivers a specific amount of drug in aerosol or solution form.• Multi-dose nasal sprays are commonly used to treat allergy related symptoms.
http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a6eaedb3-5c96-4859-be43-a48c9c818bc7&type=display 2015 MBSW
Multi-dose nasal spray
6
Delivered Dose Uniformity (DDU)
• The delivered dose measures the amount of medication delivered to the patients and should be close to the target dose as label claimed.
• Uniformity of the delivered dose is a critical quality attribute (in-vitro performance) to ensure the quality, efficacy and safety for of MDI products.
• DDU is an important requirement for batch release and quality assurance.
2015 MBSW
II. <USP> 601 DDU Test
72015 MBSW
8
USP<601> DDU Test• The test for DDU in the FDA 1999 Draft Guidance was
adopted into the 2011 in-process revision of USP <601>.
Tier 1, 10 containers (10 beginning, 10 end)
If 3~6 out of 20 (80,120)
Complies
Yes
Tier 2, additional 20 containers (20/20)
At most 6 of 60 (80%,120%)None is outside (75%, 125%)
Average of each 30 (85%,115%)
Yes Not complies
Complies
At most 2 of 20 (80%, 120%)None is outside (75%, 125%)Average of each 10 (85%,115%)
No
2015 MBSW
9
• A counting method: converts a continues variable (DD) into a binary variable (outside/inside):
Sampling by Variable vs. Sampling by Attribute• Only applicable to the samples, not for inference on the entire
batch.– No clear definition of the product quality;– Not a statistically based sampling plan.– The sample is OK ≠ The batch is OK.
• Zero Tolerance Outside (75%, 125%):– To detect extreme data. – It is no effect for small sample;– Not reward large samples;
USP<601> DDU Test
2015 MBSW
Is the USP DDU test a batch release test?
10
USP<601> DDU Test
2015 MBSW
Can the USP test make inference on the entire batch?
No. Only applicable to the samples, not for inference on the entire batch.
Is the USP test a stringent test for batch release?
No. Whenever tested, the product needs to meet the USP acceptance criteria. Thus, a batch release test is usually more stringent than the USP test.
• Needs a statistically sound approach for batch release: the tolerance interval approach controls the coverage within a specific interval (say 80 – 120%LC).
III. Two One-sided Tolerance Intervals DDU Test
112015 MBSW
12
Two One-sided Tolerance Intervals Procedure (TOSTI)
• In 2003, IPAC-RS (International Pharmaceutical Aerosol Consortium on Regulation and Science) proposed a two-sided tolerance interval approach as an improvement for the control of DDU of orally inhaled and nasal drug products.
• Coverage as the quality requirement;
• In 2005, FDA proposed a two one-sided tolerance intervals (TOSTI) procedure to test if the batch complies and presented this procedure to the Advisory Committee of Pharmaceutical Science, in October 2005.
• Coverage as the quality requirement;
2015 MBSW
13
TOSTI - Product Quality Definition• Two-sided TI: Most lot (>P%) within (80%, 120%)
• Two one-sided TIs: Not much outside each end of (80%, 120%)
• WITH 95% CONFIDENCE
PU)X(L:H
PU)X(L:H
Pr
Pr
Hypotheses sided-Two
1
0
2
1Pr and
2
1Pr
2
1Pr
2
1Pr
Hypotheses sided-One Two
1
0
PU)(X
PL)(X:H
PU)(Xor
PL)(X:H
efficacy safety
p1p2
132015 MBSW
14
• Small sample n1=10/10/20/20, P = 87.5%, L=80, U=120:
• Reject H0 if
• With L= 80% LC, U = 120% LC, PU = PL = 6.25% and Pocock alpha spending function, K1 = 2.45 at the 1st tier and K2 = 1.94 at the 2nd tier.
TOSTI - Statistical Hypotheses
14
Efficacy
Safety
1110 )Pr(: vs.Pr pLXHpL)(X:H LL
2120 )Pr(: vs.Pr pUXHpU)(X:H UU Safety
UkSXkSXL ),( 1,11
pnnZntk
2015 MBSW
Tier 1, 10 containers (10 beginning, 10 end)
20/)1(1
120**80
1)2/)1((
1 20,19(
PtFk
skXskX
Complies
Yes
Tier 2, additional 20 containers(20 beginning, 20 end)
Yes
No
Not complies
Complies
60/)1(1
120**80
2)2/)1((
1 60,59(
PtFk
skXskX
Average of each 10 (85%,115%)
Average of each 30 (85%,115%)
TOSTI – Test Flow Chart
2015 MBSW 15
16
USP<601> TOSTI
Quality Def. Not clear Coverage
Mean limit 85-115% of LC 85-115% of LC
Zero Tolerance None outside 75-125% Removed
# of Tiers2 tiers with a 1:3 ratio of sample sizes
2 tiers with a 1:3 ratio of sample sizes
Tier sample size 10/10/20/20 10/10/20/20
Tier II testing versus Tier-I
Less likely to pass at Tier-II (individual limit effect)
More likely to pass at Tier-II (design feature of the test)
TOSTI vs. USP<601>
Reference: Parametric Tolerance Interval Test for Delivered Dose Uniformity (DDU) Working Group Update, Moheb M. Nasr, Ph.D., Advisory Committee of Pharmaceutical Science October 25, 2005
2015 MBSW
1717
Acceptance probability of two one-sided tests and USP <601> DDU method for two-tier multiple-dose (10/10/20/20) with batch of on-target and off-target means.
TOSTI vs. USP <601>
2015 MBSW
18
• The requirement of the sample means between 85% and 115% almost has no impact on the acceptance probabilities for TOSTI.
Acceptance probability of One-Tier (30/30) and Two-Tier (10/10/20/20) two One-sided Tolerance Interval Approach against Standard Deviation without and with requirement on means within (85,115)% Label Claim
2015 MBSW
IV. FDA Large Sample DDU Proposal
192015 MBSW
20
FDA Large Sample DDU Proposal
• The manufacturer may use a sample size different from the USP specified sample size.
– A larger number of canisters provide more precise estimation and more powerful test for quality assurance.
– A small sample size between 10 and 30 of canisters may be more preferred if the product is less variable.
• We extend the proposed TOSTI procedure for a variety of sample sizes becayuse the USP-compendia small sample DDU test serves only for the evaluation of the samples instead of providing quality assurance to a batch.
2015 MBSW
21
FDA Large Sample DDU Proposal
• It is based on TOSTI with one tier (30/30);
• No requirement on mean values to be within (85, 115)%LC;
• Basic Idea:
– Pick up a Matching Point: a reference point (90% power) of a reference OC Curve (30/30 TOSTI OC Curve).
– All OC curves of various sample sizes intersect at the Matching Point;
– Calculate the specification for the null hypotheses (p1, p2) at α = 5%.
2015 MBSW
22
FDA Large Sample DDU Proposal
2015 MBSW
17
• Given the power function, we develop a two-step method to determine p(n*): matching on 90% power with 30/30 OC
Step 1: Solve for k subject to Step 1: Solve for k subject to
Step 2: Solve for p(n) from Step 2: Solve for p(n) from
1* 1,1 ( 5%) ( *)*
( * )n p nnk t n Z
1 2( *, , 100, 6.25%) 0.90 n k p p k
( *)p n
FDA Large Sample DDU Proposal
2015 MBSW
24
FDA Large Sample DDU Proposal
n/n 15/15 25/25 50/50 60/60 90/90 120/120 150/150 200/200
γ* = 90% 10.06 7.03 4.64 4.22 3.48 3.09 2.84 2.58
• Specifications in percentage of p0 = Pr (X < 80) = Pr (X > 120)
for one-tier TOSTI for various sample sizes n/n (n samples at beginning and n samples at end) with the matching point at γ* acceptance probability for lots with μ = 100, p0 = 6.25% for 30/30
sample size.
2015 MBSW
V. Summary
252015 MBSW
26
Summary
• TOSTI is a batch release test which controls the quality by the coverage within (80%, 120%) of the label claim;
• Furthermore, the TOSTI approach accepts a batch only if both portions of units being under-delivered (e.g. <80% efficacy concern) and over-delivered (e.g. > 120% safety concern) are controlled.
• It can be adjusted for a two-tier group sequential sampling acceptance plan:
– Additional acceptance probability at the 2nd tier;
– More discriminating power between lots with on-target mean and off-target mean.
2015 MBSW
• TOSTI approach can be easily illustrated as a procedure with two one-sided tests or with a two one-sided tolerance intervals concept with exact solutions.
• When using a single-tier sampling plan, the TOSTI procedure can also be extended to any sample size. The extension was made by protecting the acceptance rate for lots considered to be high quality in DDU.
27
Summary
2015 MBSW
Main References
• FDA Draft Guidance (1998) “FDA/CDER. Guidance for Industry “Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation”. Draft: May 1999”. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070575.pdf
• Tsong, Y., Dong, X., Shen, M., Lostritto R.T. (2015). “Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products”. Journal of Biopharmaceutical Statistics. 25(2):328-38.
• Tsong Y, Shen M, Lostritto RT, Poochikian GK (2008). Parametric two-tier sequential quality assurance test of delivery dose uniformity of multiple-dose inhaler and dry powder inhaler drug products. Journal of Biopharmaceutical Statistics, 18:5, 976-984.
• USP General Chapter <601> Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests” http://www.pharmacopeia.cn/v29240/usp29nf24s0_c601_viewall.html
2015 MBSW 28
Main References
• Moheb M. Nasr. (2005) “Parametric Tolerance Interval Test for Delivered Dose Uniformity (DDU) Working Group Update”, Ph.D., Advisory Committee of Pharmaceutical Science October 25, 2005
• Bo Olsson (2003), “A Parametric Tolerance Interval Test for Improved Control of Delivered Dose Uniformity of Orally Inhaled and Nasal Drug Products.” IPAC-RS Presentaion, Rockville, MD
2015 MBSW 29
Thank you!
302015 MBSW